UK markets closed

Biophytis S.A. (0D1W.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.0025-0.0001 (-3.85%)
At close: 07:08PM BST
Full screen
Previous close0.0026
Open0.0026
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0025 - 0.0027
52-week range0.0025 - 0.0518
Volume7,182,842
Avg. volume153,519
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.2640
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Benzinga

    Why Is Penny Stock Biophytis Trading Higher On Tuesday?

    Monday, Biophytis SA (NASDAQ:BPTS) announced the launch of a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity combined with GLP-1 receptor agonists. The OBA Phase 2 clinical study is expected to start in mid-2024, upon regulatory approvals, with the first patients expected to be treated in the second half of 2024. BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs and following hypocaloric dietin

  • Zacks

    Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up

    Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.

  • Insider Monkey

    40 Cities with the Lowest Life Expectancy in the US

    In this article, we look at 40 cities with the lowest life expectancy in the US. You can skip our section on developments in the pharmaceutical and biotech industries to enhance longevity and head over directly to 10 Cities with the Lowest Life Expectancy in the US. Average lifespan in the US climbed from just […]